Rachel Vatnsdal (J.P. Morgan) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Rachel Vatnsdal's stock ratings?

About 55% of Rachel's ratings were profitable over a one-year hold, with an average return of +10.1% per rating, measured by 13Foresight from historical prices.

Q: How is Rachel ranked?

Rachel Vatnsdal is ranked #2008 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Rachel Vatnsdal

JPM

Rachel Vatnsdal

J.P. Morgan

Wall Street Analyst

★★☆☆☆

#2008

on 13Foresight · ranked by our own returns

55%

Success Rate

+10.1%

Average Return

16 of 29 calls profitable · -12.6% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 55% of Rachel Vatnsdal's ratings turned a profit when each position was held for 1 year — averaging +10.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

12 Buy 10 Hold 1 Sell

Rachel's Stock Coverage 30 ratings · 2026-06-21

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
AVTR Avantor	Oct 09, 2025	BUY	Buy +49.6% avg upside 26 analysts	$14.00 46.13% Upside	-30.1%
RVTY Revvity	Oct 09, 2025	HOLD	Buy +5.2% avg upside 23 analysts	$100.00 0.03% Downside	+9.3%
GH Guardant Health	Sep 25, 2025	BUY	Strong Buy -5.9% avg upside 30 analysts	$70.00 46.79% Downside	+114.5%
A Agilent	Aug 28, 2025	BUY	Strong Buy +3.8% avg upside 32 analysts	$155.00 21.99% Upside	+0.1%
ADPT Adaptive Biotechnologies	Aug 18, 2025	BUY	Strong Buy +19.9% avg upside 14 analysts	—	+41.8%
CAI Caris Life Sciences, Inc.	Aug 13, 2025	BUY	Strong Buy +54.5% avg upside 20 analysts	$40.00 116.53% Upside	-51.9%
TEM Tempus AI, Inc. Class A	Aug 11, 2025	HOLD	Strong Buy +33.4% avg upside 19 analysts	$60.00 18.00% Upside	-16.9%
XRAY DENTSPLY SIRONA	Aug 10, 2025	HOLD	Buy +170.6% avg upside 25 analysts	$14.00 35.45% Upside	-13.3%
TXG 10x Genomics	Aug 08, 2025	HOLD	Buy -27.9% avg upside 18 analysts	$13.00 62.67% Downside	+158.3%
NTRA Natera	Aug 08, 2025	BUY	Strong Buy +7.4% avg upside 26 analysts	$210.00 9.24% Downside	+49.0%
BRKR Bruker	Aug 05, 2025	BUY	Buy -7.0% avg upside 22 analysts	$50.00 12.64% Downside	+71.4%
TWST Twist Bioscience	Aug 05, 2025	SELL	Strong Buy -26.4% avg upside 14 analysts	$25.00 71.45% Downside	-208.7%
WAT Waters	Aug 04, 2025	HOLD	Buy +3.6% avg upside 30 analysts	$300.00 15.69% Downside	+25.0%
ILMN Illumina	Aug 01, 2025	HOLD	Buy -10.1% avg upside 30 analysts	$100.00 38.15% Downside	+68.1%
NVST Envista Holdings	Aug 01, 2025	HOLD	Buy +12.8% avg upside 19 analysts	$20.00 22.71% Downside	+11.5%
MYGN Myriad Genetics	May 07, 2025	SELL	Hold +313.3% avg upside 24 analysts	$6.00 32.18% Upside	+4.2%
MTD Mettler-Toledo	May 05, 2025	HOLD	Buy +2.7% avg upside 18 analysts	$1200.00 4.83% Upside	+19.4%
RGEN Repligen	Apr 29, 2025	BUY	Strong Buy +28.4% avg upside 25 analysts	$190.00 43.85% Upside	-18.9%
TMO Thermo Fisher	Apr 23, 2025	BUY	Strong Buy +26.8% avg upside 38 analysts	$600.00 29.16% Upside	+8.5%
DHR Danaher	Apr 22, 2025	BUY	Strong Buy +21.9% avg upside 45 analysts	$260.00 46.84% Upside	-3.5%
PACB Pacific Biosciences	Apr 21, 2024	HOLD	Buy +213.7% avg upside 14 analysts	—	-26.9%
SEER Seer	Aug 09, 2023	HOLD	Strong Buy +551.3% avg upside 5 analysts	$5.00 187.27% Upside	-44.3%
SOPH SOPHiA GENETICS	Aug 08, 2023	BUY	Strong Buy +75.8% avg upside 7 analysts	$8.00 46.52% Upside	-5.3%
LH Labcorp Holdings	Apr 26, 2023	BUY	Strong Buy +1.8% avg upside 36 analysts	$270.00 5.49% Upside	+5.5%
HSIC Henry Schein	Mar 08, 2023	HOLD	Buy +7.4% avg upside 25 analysts	$80.00 0.06% Upside	-3.9%
RPID Rapid Micro Biosystems	Sep 06, 2022	HOLD	Strong Buy +411.7% avg upside 6 analysts	—	-71.0%
DGX Quest Diagnostics	Jul 22, 2022	HOLD	Buy -12.4% avg upside 33 analysts	$145.00 25.64% Downside	+12.4%
LAB Standard BioTools	May 10, 2020	BUY	Buy +645.3% avg upside 8 analysts	$9.00 984.66% Upside	-4.7%
CDNA CareDx	May 01, 2020	BUY	Buy +25.1% avg upside 16 analysts	$54.00 106.30% Upside	+194.5%
IMDX Insight Molecular Diagnostics	Apr 30, 2020	BUY	Buy -1.2% avg upside 10 analysts	$5.40 0.71% Downside	·

🔒 25 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Rachel Vatnsdal — Frequently Asked Questions

How accurate are Rachel Vatnsdal's stock ratings?

Based on the calls 13Foresight could measure, about 55% of Rachel's ratings were profitable over a one-year hold, with an average return of +10.1% per rating, or -12.6% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Rachel ranked on 13Foresight?

Rachel Vatnsdal is currently ranked #2008 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Rachel cover?

Rachel most recently has ratings on AVTR, RVTY, GH, A, ADPT, CAI, TEM, XRAY, TXG, NTRA, BRKR, TWST and 18 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!